An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 Compared With Sevelamer Carbonate in Dialysis Patients With Hyperphosphataemia. Extension Study for Protocol PA-CL-05A

Trial Profile

An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 Compared With Sevelamer Carbonate in Dialysis Patients With Hyperphosphataemia. Extension Study for Protocol PA-CL-05A

Completed
Phase of Trial: Phase III

Latest Information Update: 29 May 2018

At a glance

  • Drugs Sucroferric oxyhydroxide (Primary) ; Sevelamer
  • Indications Hyperphosphataemia
  • Focus Therapeutic Use
  • Sponsors Vifor
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 May 2018 Results of post-hoc analysis from both parent (NCT01324128) and extension (NCT01464190) study assessing the effects serum phosphate control and FGF-23 levels with sucroferric oxyhydraoxide and sevelamer on CKD-MBD parameters among dialysis patients who completed 1 year of treatment with sucroferric oxyhydroxide or sevelamer published in the Nephrology Dialysis Transplantation
    • 23 Feb 2017 Results (n=1055) of both parent and extension study assessing one year efficacy and safety published in the Nephrology Dialysis Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top